Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Familial breast/ovarian cancer and BRCA1/2 genetic screening: the role of immunohistochemistry as an additional method in the selection of patients.

The journal of histochemistry and cytochemistry : official journal of the Histochemistry Society - 1 Nov 2007

Vaz Fátima H, Machado Patrícia M, Brandão Rita D, Laranjeira Cátia T, Eugénio Joana S, Fernandes Aires H, André Saudade P

Abstract excerpt

Only 20-25% of families screened for BRCA1/2 mutations are found positive. Because only a positive result is informative, we studied the role of BRCA1/2 immunohistochemistry as an additional method for patient selection. From 53 high-risk-affected probands, 18 (34%) had available paraffin blocks of their tumors and were selected for this study. Mutation screening was done by conformation-sensitive gel...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Apoptosis Regulatory Proteins
Share to BRCA1 Protein

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to BRCA2 Protein

Share to Immunohistochemistry

Share to Lung Neoplasms

Share to Ovarian Neoplasms

Share to Predictive Value of Tests

Share to Rectal Neoplasms

Source

Open in PubMed Open full text

Identifiers

PMID: 17625228
DOI: 10.1369/jhc.7A7209.2007
PMCID: PMC3957528

Genes

BRCA1
BRCA2

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 6 Sept 2026. Manifest publication-graph-cohort-2026-09-06.1.

Source receipt: pubmed, retrieved 6 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Familial breast/ovarian cancer and BRCA1/2 genetic screening: the role of immunohistochemistry as an additional method in the selection of patients.PMID 17625228Read ↗

The Pathology of Familial Breast Cancer: Predictive Value of Immunohistochemical Markers Estrogen Receptor, Progesterone Receptor, HER-2, and p53 in Patients With Mutations in <i>BRCA1</i> and <i>BRCA2</i>Semantic proximity Read ↗

Validation and Implementation of BRCA1/2 Variant Screening in Ovarian Tumor Tissue.Semantic proximity Read ↗

Immunohistochemical characteristics defined by tissue microarray of hereditary breast cancer not attributable to BRCA1 or BRCA2 mutations: differences from breast carcinomas arising in BRCA1 and BRCA2 mutation carriers.Semantic proximity Read ↗

Incorporating tumor immunohistochemical markers in BRCA1 and BRCA2 carrier predictionSemantic proximity Read ↗

Phenotypic characterization of hereditary epithelial ovarian cancer based on a tissue microarray study.Semantic proximity Read ↗

Breast cancer immunohistochemical features in young women with BRCA 1/2 mutations.Semantic proximity Read ↗

Selecting for BRCA1 testing using a combination of homogeneous selection criteria and immunohistochemical characteristics of breast cancers.Semantic proximity Read ↗

Histopathological features of breast tumours in BRCA1, BRCA2 and mutation-negative breast cancer families.Semantic proximity Read ↗

Immunohistochemical expression of DNA repair proteins in familial breast cancer differentiate BRCA2-associated tumors.Semantic proximity Read ↗

Identification of BRCA1-deficient ovarian cancers.Semantic proximity Read ↗

[Morphologically qnd immunohistochemically based screening criteria for selection of patients with possible mutation of BRCA1 gene in primary ovarian cancer].Semantic proximity Read ↗

Increased frequency of TP53 mutations in BRCA1 and BRCA2 ovarian tumours.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.